MedTrace Logo

Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)

NCT00198081 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2016-02-29

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.

Conditions

  • Pancreas Neoplasms

Interventions

DRUG

COX-2 Inhibitor 6-8 weeks prior to surgery

400 mg BID 6-8 weeks prior to surgery

DRUG

COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP

400 mg BID for 6 months prior to follow-up EUS or ERCP

Sponsors & Collaborators

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Christian M. Schmidt, MD · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198081 on ClinicalTrials.gov